Medical AI startup Boltz raises $110M to speed up small molecule research

SiliconANGLE
Read full story· 4 min
Boltz PBC raised $110M in a Series A round led by Bessemer to accelerate small molecule drug research using its AI models BoltzMol-1 and BoltzProt-1, which streamline binding affinity analysis and protein design evaluation.

What happened

Boltz PBC, a company that creates AI tools for pharmaceutical research, secured $110 million in Series A funding led by Bessemer. The announcement was made on Wednesday, with several new and existing investors participating. Boltz provides AI models, BoltzMol-1 and BoltzProt-1, to help researchers analyze small molecules and design proteins more efficiently. The company plans to use the new funds to expand its team and increase computing resources.

Key details

  • $110 million raised in Series A funding
  • Funding round led by Bessemer, with participation from Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital, Hummingbird, and others
  • BoltzMol-1 model reduces the number of molecules researchers need to review from hundreds of thousands to a few dozen
  • BoltzProt-1 can generate tens of thousands of protein designs and evaluates them using direct metrics
  • Six of the world’s 20 largest pharmaceutical companies use Boltz’s algorithms, which are sold via API and billed by token usage

Why it matters

Pharmaceutical companies and researchers using Boltz’s models can now analyze and identify promising drug candidates faster and with fewer resources. This reduces both the time and cost required for early-stage drug discovery. With the additional funding, Boltz will be able to support more clients and handle larger computational workloads, potentially benefiting drug development pipelines at major pharmaceutical firms.


More in Healthcare